ClinicalTrials.gg
RecruitingNCT06739356Updated Oct 20, 2026

North American Fetal Therapy Network for Long-term Outcome Following Fetoscopic Endoluminal Tracheal Occlusion in Severe Left and Right Congenital Diaphragmatic Hernia

An interventional study of Fetal Treatment arm (FETO Group) in Congenital Diaphragmatic Hernia, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States — 24 open to participants now, 28 under way, 2 of them phase 3. Hernias, Diaphragmatic, Congenital · United States.

Planned enrollment
4th of 36
80 · median 21
Started
2025
with 6 others
No phase
28 of 45
18 open now
Primary completion
2029-12
later than 16 of 27 live
Registered
37th of 45
by date
Lead sponsor
3 of 45
The University of Texas Health Science Center, Houston

Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, this one is the 4th largest by planned enrollment of the 36 interventional ones that give a count, is one of 7 that started in 2025, is one of 28 with no phase, reaches primary completion later than 16 of the 27 other live ones, and was the 37th registered.

Hernias, Diaphragmatic, Congenital

86 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.

Browse Hernias, Diaphragmatic, Congenital studies →

Open to participants now

24 of the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Hernias, Diaphragmatic, Congenital studies recruiting now, 16 (50%) set no upper age limit and 16 (50%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate successful placement and removal of Fetoscopic Endoluminal Tracheal Occlusion (FETO) device in cases of intrathoracic liver herniation with isolated left congenital diaphragmatic hernia (LCDH) with Observed/Expected (O/E) Lung to Head Circumference Ratio (LHR) \< 30% or isolated right congenital diaphragmatic hernia (RCDH) with O/E LHR \< 45%,to compare survival to discharge from the neonatal intensive care units (NICU), between fetuses with intrathoracic liver herniation and isolated LCDH with O/E LHR \< 30% that receive FETO procedure performed at 27 weeks 0 days to 29weeks 6 days of gestation to those with intrathoracic liver herniation, isolated LCDH and o/e LRH \< 30% that undergo expectant management, to compare the neonatal survival rate to discharge from the neonatal intensive care units (NICU), between fetuses with intrathoracic liver herniation, isolated RCHD with o/e LHR \< 45% that undergo FETO procedure performed at 27 weeks 0 days to 29 weeks 6 days gestation to those with intrathoracic liver herniation, isolated RCHD and o/e LHR \< 45% that elect to proceed with expectant management, to evaluate the frequency of maternal and fetal complications associated with FETO procedure, to evaluate whether the FETO procedure is associated with reduced long-term mortality and morbidities in isolated LCDH survivors with o/e LHR \<30% when compared to isolated LCDH with o/e LRH \<30% that undergo expectant management where all fetuses were found to have intrathoracic liver herniation and to evaluate whether the FETO procedure is associated with reduced long-term mortality and morbidities in isolated RCDH survivors with o/e LHR ≤ 45% when compared to isolated RCHD with LHR \< 45% that undergo expectant management where all fetuses were found to have intrathoracic liver herniation

03

Conditions studied

  • Congenital Diaphragmatic Hernia

Keywords

  • Fetoscopic Endoluminal Tracheal Occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women who are able to consent
  • Singleton pregnancy
  • Normal Karyotype, chromosomal microanalysis (CMA) with non-pathologic variants, Whole exome sequencing (WES) or whole genome sequencing (WGS) . Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is > 26 weeks
  • Gestational age at enrollment is prior to 296 wks.
  • Intrathoracic liver herniation
  • Isolated left CDH with o/e LHR \< 30% at enrollment (180 to 295 wks.). or
  • Isolated RCDH with o/e LHR \< 45% at enrollment (180 to 295 wks.)
  • Cervical length by transvaginal ultrasound > 20 mm within 24 hours prior to FETO procedure
  • Patient meets psychosocial criteria
  • understood

Exclusion criteria

Exclusion Criteria:

  • History of natural rubber latex allergy
  • Preterm labor, cervix shortened (\<20 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa.
  • Psychosocial ineligibility, precluding consent:

    1. Inability to reside within 30 minutes of University of Texas Health Science Center at Houston Fetal Center
    2. The patient does not have a support person (e.g., spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at UTHealth Houston Fetal Center
  • Bilateral CDH, isolated left sided CDH with O/E LHR ≥ 30% (measured at 180 to 295 weeks), isolated right sided CDH with O/E LHR > 45% (measured at 180 to 295 weeks), as determined by ultrasound
  • No liver herniation into thoracic cavity
  • Additional fetal anomaly and chromosomal abnormalities by ultrasound, MRI, or echocardiogram at the fetal treatment center. Exclude chromosomal abnormalities, associated anomalies recognized to alter survival prognosis (i.e., CDH and congenital heart disease) or presence of an underlying genetic syndrome (i.e., Fryns).
  • Maternal to fetoscopic surgery or severe maternal medical condition in pregnancy
  • History of incompetent cervix with or without cerclage
  • Placental abnormalities (previa, abruption, accreta) known at time of enrollment
  • Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy
  • Maternal , Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment
  • Uterine anomalies such as large or multiple fibroids or Mullerian duct abnormality
  • There is no safe or technically feasible fetoscopic approach to balloon placement
  • Participation in another intervention study that influences maternal and fetal morbidity and mortality. or participation in this trial in a previous pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Fetal Treatment arm (FETO Group)

    Device: Fetal Treatment arm (FETO Group)

  • No intervention
    Expectant Management Arm (Control Group)

Interventions

  • DeviceFetal Treatment arm (FETO Group)

    Participants will undergo FETO surgery at at 27 weeks 0 days - 29 weeks 6 days gestation.Balloon insertion into the fetal trachea will be performed. This will be followed by weekly \\ ultrasound monitoring and MRI at 3 weeks following FETO insertion and removal of the balloon which will be performed at at 34 weeks 0 days to 34 weeks 6 days. Planned delivery will occur after 37 weeks. The follow-up phase will be conducted from birth to 24 months of age

06

What researchers measure

Primary outcomes

  1. Number of neonates that survived

    Time frame: from delivery to hospital discharge (up to 12 months)

  2. Number of Successful placement of FETO device

    Time frame: 10-60 minutes after surgery begins

  3. Number of Successful removal of FETO device

    Time frame: immediately after the procedure (about 1 hour after start of surgery)

  4. FETO procedure complications

    Complications include, Failure FETO insertion procedure, FETO device dislodgement potentially requiring a second FETO insertion, Fetal intraoperative injury, Procedural hemorrhage, Bleeding from insertion site or Abruptions, Post-procedural hemorrhage PPROM, Preterm delivery, Chorioamnion separation,Chorioamnionitis, Polyhydramnios, Oligohydramnios,Emergent removal due to obstetrical complication, Failed percutaneous or fetoscopic removal requiring cesarean section or exit procedure for removal, Neonatal death due to asphyxia if delivery before FETO removal and Non-reassuring fetal heart rate monitoring

    Time frame: end of study (24 months)

Secondary outcomes

  1. Number of infants that survived

    Time frame: 6 months

  2. Number of infants that survived

    Time frame: 12 months

  3. Number of infants that survived

    Time frame: 18 months

  4. Number of infants that survived

    Time frame: 24 months

  5. Number of infants that show presence of pulmonary hypertension

    Time frame: 6 months

  6. Number of infants that show presence of pulmonary hypertension

    Time frame: 12 months

  7. Number of infants that show presence of pulmonary hypertension

    Time frame: 18 months

  8. Number of infants that show presence of pulmonary hypertension

    Time frame: 24 months

  9. Number of infants that show need for supplemental oxygen

    Time frame: 6 months

  10. Number of infants that show need for supplemental oxygen

    Time frame: 12 months

  11. Number of infants that show need for supplemental oxygen

    Time frame: 18 months

  12. Number of infants that show need for supplemental oxygen

    Time frame: 24 months

  13. Number of infants that show periventricular leukomalacia

    Time frame: at less than 2 months postnatally

  14. Number of Infants that develop sepsis

    Time frame: 6 months

  15. Number of Infants that develop sepsis

    Time frame: 12 months

  16. Number of Infants that develop sepsis

    Time frame: 18 months

  17. Number of Infants that develop sepsis

    Time frame: 24 months

  18. Number of infants that develop Intraventricular hemorrhage (grade 0-III)

    Time frame: 6 months

  19. Number of infants that develop Intraventricular hemorrhage (grade 0-III)

    Time frame: 12 months

  20. Number of infants that develop Intraventricular hemorrhage (grade 0-III)

    Time frame: 18 months

  21. Number of infants that develop Intraventricular hemorrhage (grade 0-III)

    Time frame: 24 months

  22. Number of infants that develop retinopathy of prematurity (grade 3 or higher)

    Time frame: 6 months

  23. Number of infants that develop retinopathy of prematurity (grade 3 or higher)

    Time frame: 12 months

  24. Number of infants that develop retinopathy of prematurity (grade 3 or higher)

    Time frame: 18 months

  25. Number of infants that develop retinopathy of prematurity (grade 3 or higher)

    Time frame: 24 months

  26. Number of infants that develop gastro-esophageal reflux

    Time frame: 6 months

  27. Number of infants that develop gastro-esophageal reflux

    Time frame: 12 months

  28. Number of infants that develop gastro-esophageal reflux

    Time frame: 18 months

  29. Number of infants that develop gastro-esophageal reflux

    Time frame: 24 months

  30. Number of infant hospital readmissions

    Time frame: end of study (24 months)

  31. Cause of infant hospital readmissions

    Time frame: end of study (24 months)

  32. Number of infants that show childhood growth failure

    Time frame: 6 months

  33. Number of infants that show childhood growth failure

    Time frame: 12 months

  34. Number of infants that show childhood growth failure

    Time frame: 18 months

  35. Number of infants that show childhood growth failure

    Time frame: 24 months

  36. Number of infants that show recurrence of CDH repair

    Time frame: 6 months

  37. Number of infants that show recurrence of CDH repair

    Time frame: 12 months

  38. Number of infants that show recurrence of CDH repair

    Time frame: 18 months

  39. Number of infants that show recurrence of CDH repair

    Time frame: 24 months

  40. Number of infants that develop bowel obstruction

    Time frame: 6 months

  41. Number of infants that develop bowel obstruction

    Time frame: 12 months

  42. Number of infants that develop bowel obstruction

    Time frame: 18 months

  43. Number of infants that develop bowel obstruction

    Time frame: 24 months

  44. Number of infants that show neurodevelopmental delay as assessed by the Bayley Scales of Infant and Toddler Development-III(BSID)

    Three domains will be measured as follows: Cognitive Scale, Language Scale (Receptive and Expressive) and Motor Scale (Fine and Gross Motor Skills). Scores are derived by converting raw scores from completed tasks into scale scores and composite scores. These scores are then utilized to assess the child's performance in relation to norms established based on typically developing children of the same age Mean score of 100 (SD=15) at the 50th percentile signifies mid-average functioning. Scores below 85 (1 SD below the mean), at the 16th percentile, indicate mild impairment of being 'at risk' of developmental delay. Score below 70 (2 SD below the mean), at the second percentile, indicate moderate to severe impairment. In general, scores falling in the lowest 10th percentile indicate developmental delay

    Time frame: 24 months

  45. Number of infants that develop bronchopulmonary dysplasia

    Time frame: 6 months

  46. Number of infants that develop bronchopulmonary dysplasia

    Time frame: 12 months

  47. Number of infants that develop bronchopulmonary dysplasia

    Time frame: 18 months

  48. Number of infants that develop bronchopulmonary dysplasia

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2029, 56 months after the start.

Of 40 interventional studies with no phase under Hernias, Diaphragmatic, Congenital, half reached primary completion within 108 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 133. This study's planned 56 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 18, 2024
StartActual
Mar 4, 2025
Primary completionEst.
Dec 1, 2029
CompletionEst.
Dec 1, 2031
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06739356
Responsible party
Anthony Johnson (Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Dec 18, 2024
Start date
Mar 4, 2025
Primary completion
Dec 1, 2029 (estimated)
Completion
Dec 1, 2031 (estimated)
Last update
Oct 20, 2026

Study contacts

Anthony Johnson, DO
Contact
Anthony.Johnson@uth.tmc.edu
(713) 500-5859
Elisa Garcia
Contact
Elisa.I.Garcia@uth.tmc.edu
(713) 500-7434
Anthony Johnson, DO
principal investigator · The University of Texas Health Science Center, Houston

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion